1. Home
  2. CADL vs INM Comparison

CADL vs INM Comparison

Compare CADL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$10.84

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.36

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
INM
Founded
1999
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
7.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CADL
INM
Price
$10.84
$1.36
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
1.1M
70.6K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
58.62
62.68
EPS
N/A
N/A
Revenue
$125,000.00
$4,942,633.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.50
52 Week Low
$4.35
$0.58
52 Week High
$14.00
$2.50

Technical Indicators

Market Signals
Indicator
CADL
INM
Relative Strength Index (RSI) 41.77 48.40
Support Level $9.40 $1.35
Resistance Level $11.36 $1.40
Average True Range (ATR) 0.69 0.07
MACD -0.28 0.01
Stochastic Oscillator 27.99 47.04

Price Performance

Historical Comparison
CADL
INM

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

Share on Social Networks: